Skip to content

Foot and lower limb complications following the use of extracorporeal membrane oxygenation (ECMO): The FECMO Study. A single centre retrospective observational study.

The FECMO Study: A single centre retrospective observational study/chart audit to determine pre and peri-Extracorporeal membrane oxygenation (ECMO) explanatory variables, and the rates of foot and lower limb complications following the use of ECMO in a major tertiary hospital between 2008-2012.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ANZCTR
Registry ID
ACTRN12614000191695
Enrollment
55
Registered
2014-02-21
Start date
2013-01-02
Completion date
2014-12-31
Last updated
2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

What are the rates of foot and lower limb complications following the use of extracorporeal membrane oxygenation (ECMO) in a major Australian tertiary hospital? Our null hypothesis is that the incidence of foot and lower limb complications in patients undergoing ECMO treatment are not different to those reported in the general inpatient population.

Interventions

Patients receiving Extracorporeal membrane oxygenation (ECMO) for respiratory and/or cardiovascular failure. Observing neurovascular status, medications, offloading/pressure relieving stratergies used, foot ulceration/amputation, acute and chronic co-morbidies pre, peri and post (30 days) ECMO intervention. This data is collected via retrospective chart audit for patients receiving intervention between 01/01/2008-31/12/2012.

Sponsors

Critical Care Research Group
Lead SponsorOther Collaborative groups

Eligibility

Sex/Gender
All
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Participants receiving ECMO from January 2008- December 2012

Exclusion criteria

Patients who did not receive ECMO treatment.

Outcome results

None listed

Source: ANZCTR · Data processed: Feb 4, 2026